Glioblastoma
Conditions
Interventions
Sponsors
University of Tsukuba
Tokyo Womens Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) WHO histological grade IV glioblastoma in(GBM) supratentrial brain without dissemination. 2) Maximum surgical resection was performed. 3) 1.5 g of tumor was reserved in fixed specimen. 4) Karnofsky performance scale is equal to or more than 60 %. 5) 60 Gy of radiation will be performed. 6) Informed consent is obtained from each patient 7) Vaccination and follow-up of each patient is possible to perform within the institutions of this study. 8) Lymphocyte count in peripheral blood is 1000/mm3 or more.
Exclusion criteria
Exclusion criteria: 1) Patients who have been administered or are taking corticosteroid or anticancer drugs. 2) Patients with high intracranical pressure. 3) Patients with severe myelosupression. 4) Patients with severe complication including hematopathy 5) Patients with malignant tumor or cancer. 6) Pregnant or nursing woman, or woman willing to be pregnant. 7) Patients participate in other study during or within 6 months before temozolomide administration in this study. 8) Other reasons for exclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Cause-specific survival Progression-free survival Tumor-regression rate, disease-control rate QOL Neurological improvement | — |
Countries
Japan
Contacts
Public ContactEiichi Ishikawa
University of Tsukuba Department of Neurosurgery, Doctoral Program in Functional and Regulatory Medical Science, Graduate
Outcome results
None listed